These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22398051)

  • 41. Adalimumab for the treatment of pediatric Crohn's disease.
    Nuti F; Fiorino G; Danese S
    Expert Rev Clin Immunol; 2015; 11(9):963-72. PubMed ID: 26211396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Use of adalimumab in a patient with Crohn's disease and extensive generalised psoriasis who achieved complete remission of both conditions].
    Piqueras M; Monfort D; Pol MA; Galter S; Modolell I; Ortiz J; Boadas J
    Gastroenterol Hepatol; 2013; 36(6):396-9. PubMed ID: 23587662
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
    West RL; Zelinkova Z; Wolbink GJ; Kuipers EJ; Stokkers PC; van der Woude CJ
    Aliment Pharmacol Ther; 2008 Nov; 28(9):1122-6. PubMed ID: 18691349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab.
    Desales AL; Mendez-Navarro J; Méndez-Tovar LJ; Ortiz-Olvera NX; Cullen G; Ocampo J; Lemus W; Tun AE; Mayoral-Zavala A; Dehesa-Violante M
    J Crohns Colitis; 2012 May; 6(4):483-7. PubMed ID: 22398055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adalimumab for a co-existing clinical condition of Crohn's disease and acrodermatitis continua of Hallopeau.
    Caputo F; Parro S; Zoli G
    J Crohns Colitis; 2011 Dec; 5(6):649. PubMed ID: 22115391
    [No Abstract]   [Full Text] [Related]  

  • 49. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD; Richards R
    Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
    [No Abstract]   [Full Text] [Related]  

  • 50. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adalimumab for cutaneous metastatic Crohn's disease.
    Cury DB; Moss AC; Elias G; Nakao A
    Inflamm Bowel Dis; 2010 May; 16(5):723-4. PubMed ID: 19728388
    [No Abstract]   [Full Text] [Related]  

  • 52. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
    Ong DE; Kamm MA; Hartono JL; Lust M
    J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EBV-associated plasmablastic lymphoma in a patient with Crohn's disease after adalimumab treatment.
    Liu L; Charabaty A; Ozdemirli M
    J Crohns Colitis; 2013 Apr; 7(3):e118-9. PubMed ID: 22902264
    [No Abstract]   [Full Text] [Related]  

  • 59. Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series.
    Savarino E; Dulbecco P; Bodini G; Assandri L; Savarino V
    Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):468-70. PubMed ID: 22266834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab.
    Gupta A; Pendyala P; Arora P; Sitrin MD
    J Clin Gastroenterol; 2011 Mar; 45(3):e30-3. PubMed ID: 20975576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.